Stockscreener 앱 받기
0.00
100.00%
-90.00
전일 마감가:
$90.00
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$6.83B
수익:
$35.93M
순이익/손실:
$-244.56M
주가수익비율:
0.00
EPS:
-3.95
순현금흐름:
$-157.31M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$0.00
52주 변동 폭
$0.00
$97.14
Merus N V Stock (MRUS) Company Profile
명칭
Merus N V
전화
31 030 253 8800
주소
YALELAAN 62, 3584 CM UTRECHT
Compare MRUS vs VRTX, REGN, ARGX, ALNY, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MRUS
Merus N V
|
0.00 | 6.83B | 35.93M | -244.56M | -157.31M | -3.95 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Merus N V Stock (MRUS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-17 | 개시 | Barclays | Overweight |
| 2025-08-25 | 개시 | Alliance Global Partners | Buy |
| 2025-02-13 | 개시 | Piper Sandler | Overweight |
| 2025-02-07 | 개시 | Wells Fargo | Overweight |
| 2024-11-21 | 개시 | Goldman | Buy |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-03-28 | 개시 | Truist | Buy |
| 2024-03-04 | 재확인 | Needham | Buy |
| 2023-11-02 | 개시 | Canaccord Genuity | Buy |
| 2023-08-21 | 개시 | TD Cowen | Outperform |
| 2022-08-02 | 개시 | Stifel | Buy |
| 2022-02-11 | 개시 | BMO Capital Markets | Outperform |
| 2022-02-10 | 개시 | Needham | Buy |
| 2021-11-17 | 재개 | Guggenheim | Buy |
| 2021-06-07 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-04-08 | 개시 | William Blair | Outperform |
| 2021-03-16 | 개시 | SVB Leerink | Outperform |
| 2020-06-26 | 개시 | H.C. Wainwright | Buy |
| 2020-05-27 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-20 | 재개 | Guggenheim | Buy |
| 2019-06-28 | 개시 | ROTH Capital | Buy |
| 2019-04-12 | 재개 | Guggenheim | Buy |
| 2019-04-03 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-03-27 | 개시 | Berenberg | Buy |
| 2018-01-02 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2017-03-21 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2016-12-22 | 업그레이드 | Citigroup | Neutral → Buy |
| 2016-11-07 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2016-06-13 | 개시 | Citigroup | Buy |
| 2016-06-13 | 개시 | Guggenheim | Buy |
| 2016-06-13 | 개시 | Wedbush | Outperform |
모두보기
Merus N V 주식(MRUS)의 최신 뉴스
Trade Report: Is Merus NV on track to beat earnings2026 Short Interest & Daily Momentum Trading Reports - baoquankhu1.vn
Aug Weekly: Is Merus NV being accumulated by smart money2026 Analyst Calls & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
US Market Wrap: What hedge funds are buying Merus NVInflation Watch & Reliable Intraday Trade Alerts - baoquankhu1.vn
Merus NV Stock: Genmab Acquisition Deal at $97 Per Share Reshapes Biotech Investment Landscape for N - AD HOC NEWS
Bank Watch: Is Merus NV on track to beat earningsWeekly Investment Report & Capital Efficiency Focused Strategies - baoquankhu1.vn
Bull Run: Can Merus NV reach all time highs this year2026 Buyback Activity & Safe Entry Zone Tips - baoquankhu1.vn
Wells Fargo Downgrades Merus N.V. (MRUS) - MSN
Genmab Agrees to Buy Cancer Drugmaker Merus for $8 Billion - MSN
Stock Recap: Can Merus NV reach all time highs this yearRate Hike & Target Return Focused Stock Picks - baoquankhu1.vn
Merus NV Stock (ISIN: NL0011375928) Gains Momentum on Bispecific Antibody Pipeline Progress - AD HOC NEWS
Merus Buyout Rumor Gets Retail Traders Buzzing — Genmab Said To Be Leading The Race - MSN
Growth Review: Is Merus NV a good ESG investment2026 Setups & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Precision Trading with Merus N.v. (MRUS) Risk Zones - Stock Traders Daily
How Merus N.V. stock reacts to bond yieldsTrade Analysis Report & Low Risk Profit Maximizing Plans - Naître et grandir
Dividend Watch: Is Merus NV being accumulated by smart moneyMarket Sentiment Review & Consistent Profit Trade Alerts - baoquankhu1.vn
Merus N.V. (MRUS) Stock Analysis: Potential Upside In The Biotech Sector - DirectorsTalk Interviews
Aug Summary: Is Merus NV a good ESG investment2025 Big Picture & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
Merus N.V. (MRUS) Stock Analysis: Biotechnology Gem With 7.78% Potential Upside - DirectorsTalk Interviews
Genmab Publishes 2025 Annual Report - GlobeNewswire
Bank of America Securities Maintained a Buy Rating on Merus N.V (MRUS) - MSN
What is Merus N.V. s 5 year growth outlookWeekly Stock Summary & AI Enhanced Trading Signals - mfd.ru
Targets Report: Will Merus N.V. stock outperform tech sector in 2025Weekly Trade Summary & Reliable Momentum Entry Alerts - mfd.ru
Genmab Prepares For Two Product Launches In 2027, Both From Recent Deals - Citeline News & Insights
Is Merus N.V. stock trading near support levelsJuly 2025 PostEarnings & Intraday High Probability Setup Alerts - mfd.ru
Published on: 2026-02-10 12:58:35 - mfd.ru
Can Merus N.V. reach all time highs this year2025 Major Catalysts & Proven Capital Preservation Methods - mfd.ru
Merus N.V. (MRUS) Stock Analysis: Weighing The 7.78% Potential Upside For Investors - DirectorsTalk Interviews
Merus N.V. (MRUS) Stock Analysis: Exploring the Potential 7.78% Upside in the Biotech Sector - DirectorsTalk Interviews
Analyst Downgrade: Is Merus NV gaining market shareJuly 2025 Macro Moves & Daily Stock Momentum Reports - baoquankhu1.vn
Growth Recap: What are Can Fite BioPharma Ltd Depositary Receipts technical support levels - baoquankhu1.vn
Aug Ideas: Is Merus NV a turnaround storyJuly 2025 PreEarnings & AI Enhanced Execution Alerts - baoquankhu1.vn
Fourteen option delistings on January 21st - TipRanks
Merus N.V. (MRUS) Stock Analysis: Biotechnology Innovator With 7.78% Upside Potential - DirectorsTalk Interviews
Piper Sandler sets $84 target on Merus stock, cites drug potential - MSN
S P Trends: How does Merus NV correlate with Nasdaq2025 Technical Overview & Target Return Focused Picks - baoquankhu1.vn
Merus N.V. (MRUS) Stock Analysis: Healthcare Innovator With 7.78% Upside Potential - DirectorsTalk Interviews
Gap Down: Is Merus N.V. stock a safe haven assetJuly 2025 Trade Ideas & Risk Controlled Swing Alerts - Bộ Nội Vụ
Aug Breakouts: Why Merus NV stock could benefit from AI revolutionJuly 2025 Final Week & Stock Market Timing Techniques - Bộ Nội Vụ
Risk Report: Will Merus NV stock benefit from M A activityQuarterly Market Summary & Pattern Based Trade Signal System - Bộ Nội Vụ
Aug Shorts: Is Merus NV stock a buy on dipsEarnings Growth Summary & Low Risk Entry Point Tips - Bộ Nội Vụ
(MRUS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Published on: 2026-01-13 00:53:02 - Улправда
Merus N.V.Common Shares (NQ: MRUS - FinancialContent
How Merus N.V. stock trades before earnings2025 Market Overview & Weekly Chart Analysis and Trade Guides - ulpravda.ru
Net current asset value per share of Merus N.V. – MUN:2GH - TradingView — Track All Markets
Why Merus N.V. stock attracts high net worth investorsQuarterly Performance Summary & Reliable Entry Point Trade Alerts - ulpravda.ru
Is Merus N.V. (2GH) stock positioned for digital growth eraDay Trading Setups & Free Tools to Monitor Market Corrections - Улправда
Merus N.V. Financial Disclosures & Filings - TradingView — Track All Markets
Merus N.V. (MRUS) Stock Analysis: Exploring a 7.78% Potential Upside Amid Biotech Innovations - DirectorsTalk Interviews
Genmab Announces $2.5 Billion Note Offering for Merus Acquisition - MSN
What analysts say about Merus NV stockTrading Volume Surges & Outstanding Investment Returns - earlytimes.in
Merus N V (MRUS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.49%
1.47%
자본화:
|
볼륨(24시간):